Kavita ici final master 1226
2025-12-29
read master
plot 1year
plot 2year
plot 3year
plot 4year
plot 5year
final_master_1year
final_master_2year
final_master_3year
# final_master_4year
# final_master_5year
1year
| Characteristic | N = 9,8741 |
|---|---|
| Age | 69 (60, 77) |
| Gender_Legal_Sex | |
| Female | 4,731 (48%) |
| Male | 5,143 (52%) |
| male | |
| 0 | 4,731 (48%) |
| 1 | 5,143 (52%) |
| Race | |
| Asian | 295 (3.0%) |
| Black | 284 (2.9%) |
| Other/Unknown | 418 (4.2%) |
| White | 8,877 (90%) |
| Ethnic_Group | |
| Hispanic | 9,272 (94%) |
| Non_hispanic | 602 (6.1%) |
| ckd_incidence_1year | |
| 0 | 9,618 (97%) |
| 1 | 256 (2.6%) |
| ckd_progression_1year | |
| 0 | 8,785 (89%) |
| 1 | 1,089 (11%) |
| eskd_composite_1year | |
| 0 | 9,843 (100%) |
| 1 | 31 (0.3%) |
| ckd_composite_1year | |
| 0 | 8,517 (86%) |
| 1 | 1,357 (14%) |
| ckd_stage_1year | |
| 1 | 4,083 (41%) |
| 2 | 4,050 (41%) |
| 3 | 1,623 (16%) |
| 4 | 105 (1.1%) |
| 5 | 13 (0.1%) |
| ckd_stage_baseline | |
| 1 | 4,540 (46%) |
| 2 | 3,978 (40%) |
| 3 | 1,278 (13%) |
| 4 | 74 (0.7%) |
| 5 | 4 (<0.1%) |
| dm | |
| 0 | 8,526 (86%) |
| 1 | 1,348 (14%) |
| htn | |
| 0 | 4,047 (41%) |
| 1 | 5,827 (59%) |
| cad | |
| 0 | 7,807 (79%) |
| 1 | 2,067 (21%) |
| ace_arb | |
| 0 | 5,491 (56%) |
| 1 | 4,383 (44%) |
| diu | |
| 0 | 4,668 (47%) |
| 1 | 5,206 (53%) |
| ppi | |
| 0 | 2,768 (28%) |
| 1 | 7,106 (72%) |
| steroids | |
| 0 | 2,678 (27%) |
| 1 | 7,196 (73%) |
| smoking | |
| 0 | 4,856 (49%) |
| 1 | 5,018 (51%) |
| Bevacizumab | |
| 0 | 9,220 (93%) |
| 1 | 654 (6.6%) |
| Cisplatin | |
| 0 | 8,581 (87%) |
| 1 | 1,293 (13%) |
| Carboplatin | |
| 0 | 6,833 (69%) |
| 1 | 3,041 (31%) |
| Pemetrexed | |
| 0 | 8,561 (87%) |
| 1 | 1,313 (13%) |
| Gemcitabine | |
| 0 | 8,674 (88%) |
| 1 | 1,200 (12%) |
| Cetuximab | |
| 0 | 9,651 (98%) |
| 1 | 223 (2.3%) |
| Trastuzumab | |
| 0 | 9,588 (97%) |
| 1 | 286 (2.9%) |
| VEGF_TKI | |
| 0 | 9,044 (92%) |
| 1 | 830 (8.4%) |
| pre_CRE_180days | 0.86 (0.72, 1.04) |
| pre_HGB_180days | 12.70 (11.40, 13.80) |
| Unknown | 10 |
| pre_ALB_180days | 4.10 (3.90, 4.40) |
| Unknown | 39 |
| eGFR_CRE_baseline | 88 (71, 99) |
| 1 Median (Q1, Q3); n (%) | |
2year
| Characteristic | N = 6,1701 |
|---|---|
| Age | 69 (61, 77) |
| Gender_Legal_Sex | |
| Female | 2,901 (47%) |
| Male | 3,269 (53%) |
| male | |
| 0 | 2,901 (47%) |
| 1 | 3,269 (53%) |
| Race | |
| Asian | 166 (2.7%) |
| Black | 158 (2.6%) |
| Other/Unknown | 246 (4.0%) |
| White | 5,600 (91%) |
| Ethnic_Group | |
| Hispanic | 5,787 (94%) |
| Non_hispanic | 383 (6.2%) |
| ckd_incidence_2year | |
| 0 | 5,839 (95%) |
| 1 | 331 (5.4%) |
| ckd_progression_2year | |
| 0 | 5,441 (88%) |
| 1 | 729 (12%) |
| eskd_composite_2year | |
| 0 | 6,144 (100%) |
| 1 | 26 (0.4%) |
| ckd_composite_2year | |
| 0 | 5,101 (83%) |
| 1 | 1,069 (17%) |
| ckd_stage_1year | |
| 1 | 2,396 (39%) |
| 2 | 2,685 (44%) |
| 3 | 1,031 (17%) |
| 4 | 54 (0.9%) |
| 5 | 4 (<0.1%) |
| ckd_stage_2year | |
| 1 | 2,302 (37%) |
| 2 | 2,722 (44%) |
| 3 | 1,071 (17%) |
| 4 | 67 (1.1%) |
| 5 | 8 (0.1%) |
| ckd_stage_baseline | |
| 1 | 2,792 (45%) |
| 2 | 2,558 (41%) |
| 3 | 775 (13%) |
| 4 | 42 (0.7%) |
| 5 | 3 (<0.1%) |
| dm | |
| 0 | 5,365 (87%) |
| 1 | 805 (13%) |
| htn | |
| 0 | 2,552 (41%) |
| 1 | 3,618 (59%) |
| cad | |
| 0 | 4,915 (80%) |
| 1 | 1,255 (20%) |
| ace_arb | |
| 0 | 3,340 (54%) |
| 1 | 2,830 (46%) |
| diu | |
| 0 | 2,961 (48%) |
| 1 | 3,209 (52%) |
| ppi | |
| 0 | 1,718 (28%) |
| 1 | 4,452 (72%) |
| steroids | |
| 0 | 1,710 (28%) |
| 1 | 4,460 (72%) |
| smoking | |
| 0 | 3,014 (49%) |
| 1 | 3,156 (51%) |
| Bevacizumab | |
| 0 | 5,818 (94%) |
| 1 | 352 (5.7%) |
| Cisplatin | |
| 0 | 5,395 (87%) |
| 1 | 775 (13%) |
| Carboplatin | |
| 0 | 4,450 (72%) |
| 1 | 1,720 (28%) |
| Pemetrexed | |
| 0 | 5,383 (87%) |
| 1 | 787 (13%) |
| Gemcitabine | |
| 0 | 5,481 (89%) |
| 1 | 689 (11%) |
| Cetuximab | |
| 0 | 6,053 (98%) |
| 1 | 117 (1.9%) |
| Trastuzumab | |
| 0 | 5,998 (97%) |
| 1 | 172 (2.8%) |
| VEGF_TKI | |
| 0 | 5,616 (91%) |
| 1 | 554 (9.0%) |
| pre_CRE_180days | 0.86 (0.72, 1.04) |
| pre_HGB_180days | 12.80 (11.50, 14.00) |
| Unknown | 6 |
| pre_ALB_180days | 4.20 (3.90, 4.40) |
| Unknown | 26 |
| eGFR_CRE_baseline | 88 (72, 99) |
| 1 Median (Q1, Q3); n (%) | |
3year
| Characteristic | N = 3,8421 |
|---|---|
| Age | 70 (61, 77) |
| Gender_Legal_Sex | |
| Female | 1,768 (46%) |
| Male | 2,074 (54%) |
| male | |
| 0 | 1,768 (46%) |
| 1 | 2,074 (54%) |
| Race | |
| Asian | 85 (2.2%) |
| Black | 87 (2.3%) |
| Other/Unknown | 147 (3.8%) |
| White | 3,523 (92%) |
| Ethnic_Group | |
| Hispanic | 3,603 (94%) |
| Non_hispanic | 239 (6.2%) |
| ckd_incidence_3year | |
| 0 | 3,562 (93%) |
| 1 | 280 (7.3%) |
| ckd_progression_3year | |
| 0 | 3,402 (89%) |
| 1 | 440 (11%) |
| eskd_composite_3year | |
| 0 | 3,823 (100%) |
| 1 | 19 (0.5%) |
| ckd_composite_3year | |
| 0 | 3,114 (81%) |
| 1 | 728 (19%) |
| ckd_stage_1year | |
| 1 | 1,487 (39%) |
| 2 | 1,703 (44%) |
| 3 | 621 (16%) |
| 4 | 28 (0.7%) |
| 5 | 3 (<0.1%) |
| ckd_stage_2year | |
| 1 | 1,413 (37%) |
| 2 | 1,759 (46%) |
| 3 | 638 (17%) |
| 4 | 30 (0.8%) |
| 5 | 2 (<0.1%) |
| ckd_stage_3year | |
| 1 | 1,360 (35%) |
| 2 | 1,781 (46%) |
| 3 | 644 (17%) |
| 4 | 49 (1.3%) |
| 5 | 8 (0.2%) |
| ckd_stage_baseline | |
| 1 | 1,751 (46%) |
| 2 | 1,601 (42%) |
| 3 | 469 (12%) |
| 4 | 19 (0.5%) |
| 5 | 2 (<0.1%) |
| dm | |
| 0 | 3,372 (88%) |
| 1 | 470 (12%) |
| htn | |
| 0 | 1,567 (41%) |
| 1 | 2,275 (59%) |
| cad | |
| 0 | 3,091 (80%) |
| 1 | 751 (20%) |
| ace_arb | |
| 0 | 2,039 (53%) |
| 1 | 1,803 (47%) |
| diu | |
| 0 | 1,816 (47%) |
| 1 | 2,026 (53%) |
| ppi | |
| 0 | 1,041 (27%) |
| 1 | 2,801 (73%) |
| steroids | |
| 0 | 1,060 (28%) |
| 1 | 2,782 (72%) |
| smoking | |
| 0 | 1,850 (48%) |
| 1 | 1,992 (52%) |
| Bevacizumab | |
| 0 | 3,645 (95%) |
| 1 | 197 (5.1%) |
| Cisplatin | |
| 0 | 3,399 (88%) |
| 1 | 443 (12%) |
| Carboplatin | |
| 0 | 2,880 (75%) |
| 1 | 962 (25%) |
| Pemetrexed | |
| 0 | 3,360 (87%) |
| 1 | 482 (13%) |
| Gemcitabine | |
| 0 | 3,472 (90%) |
| 1 | 370 (9.6%) |
| Cetuximab | |
| 0 | 3,780 (98%) |
| 1 | 62 (1.6%) |
| Trastuzumab | |
| 0 | 3,755 (98%) |
| 1 | 87 (2.3%) |
| VEGF_TKI | |
| 0 | 3,511 (91%) |
| 1 | 331 (8.6%) |
| pre_CRE_180days | 0.87 (0.73, 1.04) |
| pre_HGB_180days | 12.90 (11.70, 14.10) |
| Unknown | 5 |
| pre_ALB_180days | 4.20 (3.90, 4.40) |
| Unknown | 15 |
| eGFR_CRE_baseline | 88 (72, 99) |
| 1 Median (Q1, Q3); n (%) | |
4year
| Characteristic | N = 2,5351 |
|---|---|
| Age | 70 (61, 77) |
| Gender_Legal_Sex | |
| Female | 1,163 (46%) |
| Male | 1,372 (54%) |
| male | |
| 0 | 1,163 (46%) |
| 1 | 1,372 (54%) |
| Race | |
| Asian | 52 (2.1%) |
| Black | 46 (1.8%) |
| Other/Unknown | 95 (3.7%) |
| White | 2,342 (92%) |
| Ethnic_Group | |
| Hispanic | 2,366 (93%) |
| Non_hispanic | 169 (6.7%) |
| ckd_incidence_4year | |
| 0 | 2,315 (91%) |
| 1 | 220 (8.7%) |
| ckd_progression_4year | |
| 0 | 2,254 (89%) |
| 1 | 281 (11%) |
| eskd_composite_4year | |
| 0 | 2,522 (99%) |
| 1 | 13 (0.5%) |
| ckd_composite_4year | |
| 0 | 2,027 (80%) |
| 1 | 508 (20%) |
| ckd_stage_1year | |
| 1 | 980 (39%) |
| 2 | 1,151 (45%) |
| 3 | 383 (15%) |
| 4 | 19 (0.7%) |
| 5 | 2 (<0.1%) |
| ckd_stage_2year | |
| 1 | 941 (37%) |
| 2 | 1,179 (47%) |
| 3 | 396 (16%) |
| 4 | 18 (0.7%) |
| 5 | 1 (<0.1%) |
| ckd_stage_3year | |
| 1 | 882 (35%) |
| 2 | 1,220 (48%) |
| 3 | 408 (16%) |
| 4 | 22 (0.9%) |
| 5 | 3 (0.1%) |
| ckd_stage_4year | |
| 1 | 918 (36%) |
| 2 | 1,144 (45%) |
| 3 | 445 (18%) |
| 4 | 26 (1.0%) |
| 5 | 2 (<0.1%) |
| ckd_stage_baseline | |
| 1 | 1,177 (46%) |
| 2 | 1,046 (41%) |
| 3 | 302 (12%) |
| 4 | 9 (0.4%) |
| 5 | 1 (<0.1%) |
| dm | |
| 0 | 2,238 (88%) |
| 1 | 297 (12%) |
| htn | |
| 0 | 1,024 (40%) |
| 1 | 1,511 (60%) |
| cad | |
| 0 | 2,037 (80%) |
| 1 | 498 (20%) |
| ace_arb | |
| 0 | 1,326 (52%) |
| 1 | 1,209 (48%) |
| diu | |
| 0 | 1,202 (47%) |
| 1 | 1,333 (53%) |
| ppi | |
| 0 | 639 (25%) |
| 1 | 1,896 (75%) |
| steroids | |
| 0 | 720 (28%) |
| 1 | 1,815 (72%) |
| smoking | |
| 0 | 1,223 (48%) |
| 1 | 1,312 (52%) |
| Bevacizumab | |
| 0 | 2,413 (95%) |
| 1 | 122 (4.8%) |
| Cisplatin | |
| 0 | 2,260 (89%) |
| 1 | 275 (11%) |
| Carboplatin | |
| 0 | 1,971 (78%) |
| 1 | 564 (22%) |
| Pemetrexed | |
| 0 | 2,246 (89%) |
| 1 | 289 (11%) |
| Gemcitabine | |
| 0 | 2,312 (91%) |
| 1 | 223 (8.8%) |
| Cetuximab | |
| 0 | 2,502 (99%) |
| 1 | 33 (1.3%) |
| Trastuzumab | |
| 0 | 2,480 (98%) |
| 1 | 55 (2.2%) |
| VEGF_TKI | |
| 0 | 2,335 (92%) |
| 1 | 200 (7.9%) |
| pre_CRE_180days | 0.87 (0.73, 1.04) |
| pre_HGB_180days | 13.10 (11.80, 14.10) |
| Unknown | 1 |
| pre_ALB_180days | 4.20 (3.90, 4.40) |
| Unknown | 8 |
| eGFR_CRE_baseline | 88 (72, 99) |
| 1 Median (Q1, Q3); n (%) | |
5year
| Characteristic | N = 1,7191 |
|---|---|
| Age | 70 (61, 78) |
| Gender_Legal_Sex | |
| Female | 789 (46%) |
| Male | 930 (54%) |
| male | |
| 0 | 789 (46%) |
| 1 | 930 (54%) |
| Race | |
| Asian | 38 (2.2%) |
| Black | 26 (1.5%) |
| Other/Unknown | 60 (3.5%) |
| White | 1,595 (93%) |
| Ethnic_Group | |
| Hispanic | 1,598 (93%) |
| Non_hispanic | 121 (7.0%) |
| ckd_incidence_5year | |
| 0 | 1,545 (90%) |
| 1 | 174 (10%) |
| ckd_progression_5year | |
| 0 | 1,542 (90%) |
| 1 | 177 (10%) |
| eskd_composite_5year | |
| 0 | 1,706 (99%) |
| 1 | 13 (0.8%) |
| ckd_composite_5year | |
| 0 | 1,362 (79%) |
| 1 | 357 (21%) |
| ckd_stage_1year | |
| 1 | 681 (40%) |
| 2 | 775 (45%) |
| 3 | 252 (15%) |
| 4 | 9 (0.5%) |
| 5 | 2 (0.1%) |
| ckd_stage_2year | |
| 1 | 636 (37%) |
| 2 | 813 (47%) |
| 3 | 259 (15%) |
| 4 | 10 (0.6%) |
| 5 | 1 (<0.1%) |
| ckd_stage_3year | |
| 1 | 590 (34%) |
| 2 | 849 (49%) |
| 3 | 268 (16%) |
| 4 | 9 (0.5%) |
| 5 | 3 (0.2%) |
| ckd_stage_4year | |
| 1 | 616 (36%) |
| 2 | 799 (46%) |
| 3 | 287 (17%) |
| 4 | 15 (0.9%) |
| 5 | 2 (0.1%) |
| ckd_stage_5year | |
| 1 | 628 (37%) |
| 2 | 787 (46%) |
| 3 | 281 (16%) |
| 4 | 20 (1.2%) |
| 5 | 3 (0.2%) |
| ckd_stage_baseline | |
| 1 | 819 (48%) |
| 2 | 706 (41%) |
| 3 | 188 (11%) |
| 4 | 6 (0.3%) |
| 5 | 0 (0%) |
| dm | |
| 0 | 1,536 (89%) |
| 1 | 183 (11%) |
| htn | |
| 0 | 694 (40%) |
| 1 | 1,025 (60%) |
| cad | |
| 0 | 1,399 (81%) |
| 1 | 320 (19%) |
| ace_arb | |
| 0 | 908 (53%) |
| 1 | 811 (47%) |
| diu | |
| 0 | 810 (47%) |
| 1 | 909 (53%) |
| ppi | |
| 0 | 418 (24%) |
| 1 | 1,301 (76%) |
| steroids | |
| 0 | 497 (29%) |
| 1 | 1,222 (71%) |
| smoking | |
| 0 | 830 (48%) |
| 1 | 889 (52%) |
| Bevacizumab | |
| 0 | 1,643 (96%) |
| 1 | 76 (4.4%) |
| Cisplatin | |
| 0 | 1,535 (89%) |
| 1 | 184 (11%) |
| Carboplatin | |
| 0 | 1,360 (79%) |
| 1 | 359 (21%) |
| Pemetrexed | |
| 0 | 1,545 (90%) |
| 1 | 174 (10%) |
| Gemcitabine | |
| 0 | 1,573 (92%) |
| 1 | 146 (8.5%) |
| Cetuximab | |
| 0 | 1,698 (99%) |
| 1 | 21 (1.2%) |
| Trastuzumab | |
| 0 | 1,684 (98%) |
| 1 | 35 (2.0%) |
| VEGF_TKI | |
| 0 | 1,606 (93%) |
| 1 | 113 (6.6%) |
| pre_CRE_180days | 0.86 (0.73, 1.03) |
| pre_HGB_180days | 13.10 (11.90, 14.20) |
| Unknown | 1 |
| pre_ALB_180days | 4.20 (3.90, 4.40) |
| Unknown | 7 |
| eGFR_CRE_baseline | 89 (73, 100) |
| 1 Median (Q1, Q3); n (%) | |
6year
| Characteristic | N = 1,1201 |
|---|---|
| Age | 70 (61, 77) |
| Gender_Legal_Sex | |
| Female | 521 (47%) |
| Male | 599 (53%) |
| male | |
| 0 | 521 (47%) |
| 1 | 599 (53%) |
| Race | |
| Asian | 19 (1.7%) |
| Black | 23 (2.1%) |
| Other/Unknown | 41 (3.7%) |
| White | 1,037 (93%) |
| Ethnic_Group | |
| Hispanic | 1,032 (92%) |
| Non_hispanic | 88 (7.9%) |
| ckd_incidence_6year | |
| 0 | 998 (89%) |
| 1 | 122 (11%) |
| ckd_progression_6year | |
| 0 | 1,006 (90%) |
| 1 | 114 (10%) |
| eskd_composite_6year | |
| 0 | 1,111 (99%) |
| 1 | 9 (0.8%) |
| ckd_composite_6year | |
| 0 | 881 (79%) |
| 1 | 239 (21%) |
| ckd_stage_1year | |
| 1 | 469 (42%) |
| 2 | 497 (44%) |
| 3 | 149 (13%) |
| 4 | 4 (0.4%) |
| 5 | 1 (<0.1%) |
| ckd_stage_2year | |
| 1 | 424 (38%) |
| 2 | 539 (48%) |
| 3 | 154 (14%) |
| 4 | 2 (0.2%) |
| 5 | 1 (<0.1%) |
| ckd_stage_3year | |
| 1 | 388 (35%) |
| 2 | 560 (50%) |
| 3 | 167 (15%) |
| 4 | 4 (0.4%) |
| 5 | 1 (<0.1%) |
| ckd_stage_4year | |
| 1 | 417 (37%) |
| 2 | 524 (47%) |
| 3 | 173 (15%) |
| 4 | 5 (0.4%) |
| 5 | 1 (<0.1%) |
| ckd_stage_5year | |
| 1 | 428 (38%) |
| 2 | 512 (46%) |
| 3 | 168 (15%) |
| 4 | 10 (0.9%) |
| 5 | 2 (0.2%) |
| ckd_stage_6year | |
| 1 | 415 (37%) |
| 2 | 515 (46%) |
| 3 | 173 (15%) |
| 4 | 14 (1.3%) |
| 5 | 3 (0.3%) |
| ckd_stage_baseline | |
| 1 | 549 (49%) |
| 2 | 450 (40%) |
| 3 | 119 (11%) |
| 4 | 2 (0.2%) |
| 5 | 0 (0%) |
| dm | |
| 0 | 1,004 (90%) |
| 1 | 116 (10%) |
| htn | |
| 0 | 448 (40%) |
| 1 | 672 (60%) |
| cad | |
| 0 | 924 (83%) |
| 1 | 196 (18%) |
| ace_arb | |
| 0 | 597 (53%) |
| 1 | 523 (47%) |
| diu | |
| 0 | 543 (48%) |
| 1 | 577 (52%) |
| ppi | |
| 0 | 245 (22%) |
| 1 | 875 (78%) |
| steroids | |
| 0 | 318 (28%) |
| 1 | 802 (72%) |
| smoking | |
| 0 | 552 (49%) |
| 1 | 568 (51%) |
| Bevacizumab | |
| 0 | 1,072 (96%) |
| 1 | 48 (4.3%) |
| Cisplatin | |
| 0 | 1,000 (89%) |
| 1 | 120 (11%) |
| Carboplatin | |
| 0 | 902 (81%) |
| 1 | 218 (19%) |
| Pemetrexed | |
| 0 | 1,016 (91%) |
| 1 | 104 (9.3%) |
| Gemcitabine | |
| 0 | 1,035 (92%) |
| 1 | 85 (7.6%) |
| Cetuximab | |
| 0 | 1,109 (99%) |
| 1 | 11 (1.0%) |
| Trastuzumab | |
| 0 | 1,098 (98%) |
| 1 | 22 (2.0%) |
| VEGF_TKI | |
| 0 | 1,051 (94%) |
| 1 | 69 (6.2%) |
| pre_CRE_180days | 0.86 (0.72, 1.03) |
| pre_HGB_180days | 13.20 (12.00, 14.20) |
| pre_ALB_180days | 4.20 (3.90, 4.40) |
| Unknown | 3 |
| eGFR_CRE_baseline | 90 (74, 101) |
| 1 Median (Q1, Q3); n (%) | |
7year
| Characteristic | N = 6821 |
|---|---|
| Age | 70 (61, 78) |
| Gender_Legal_Sex | |
| Female | 306 (45%) |
| Male | 376 (55%) |
| male | |
| 0 | 306 (45%) |
| 1 | 376 (55%) |
| Race | |
| Asian | 9 (1.3%) |
| Black | 15 (2.2%) |
| Other/Unknown | 26 (3.8%) |
| White | 632 (93%) |
| Ethnic_Group | |
| Hispanic | 627 (92%) |
| Non_hispanic | 55 (8.1%) |
| ckd_incidence_7year | |
| 0 | 594 (87%) |
| 1 | 88 (13%) |
| ckd_progression_7year | |
| 0 | 614 (90%) |
| 1 | 68 (10.0%) |
| eskd_composite_7year | |
| 0 | 673 (99%) |
| 1 | 9 (1.3%) |
| ckd_composite_7year | |
| 0 | 525 (77%) |
| 1 | 157 (23%) |
| ckd_stage_1year | |
| 1 | 295 (43%) |
| 2 | 302 (44%) |
| 3 | 81 (12%) |
| 4 | 3 (0.4%) |
| 5 | 1 (0.1%) |
| ckd_stage_2year | |
| 1 | 272 (40%) |
| 2 | 320 (47%) |
| 3 | 88 (13%) |
| 4 | 1 (0.1%) |
| 5 | 1 (0.1%) |
| ckd_stage_3year | |
| 1 | 251 (37%) |
| 2 | 332 (49%) |
| 3 | 97 (14%) |
| 4 | 1 (0.1%) |
| 5 | 1 (0.1%) |
| ckd_stage_4year | |
| 1 | 260 (38%) |
| 2 | 316 (46%) |
| 3 | 101 (15%) |
| 4 | 4 (0.6%) |
| 5 | 1 (0.1%) |
| ckd_stage_5year | |
| 1 | 268 (39%) |
| 2 | 309 (45%) |
| 3 | 98 (14%) |
| 4 | 5 (0.7%) |
| 5 | 2 (0.3%) |
| ckd_stage_6year | |
| 1 | 261 (38%) |
| 2 | 314 (46%) |
| 3 | 97 (14%) |
| 4 | 8 (1.2%) |
| 5 | 2 (0.3%) |
| ckd_stage_7year | |
| 1 | 247 (36%) |
| 2 | 323 (47%) |
| 3 | 97 (14%) |
| 4 | 11 (1.6%) |
| 5 | 4 (0.6%) |
| ckd_stage_baseline | |
| 1 | 348 (51%) |
| 2 | 264 (39%) |
| 3 | 68 (10.0%) |
| 4 | 2 (0.3%) |
| 5 | 0 (0%) |
| dm | |
| 0 | 603 (88%) |
| 1 | 79 (12%) |
| htn | |
| 0 | 259 (38%) |
| 1 | 423 (62%) |
| cad | |
| 0 | 575 (84%) |
| 1 | 107 (16%) |
| ace_arb | |
| 0 | 363 (53%) |
| 1 | 319 (47%) |
| diu | |
| 0 | 324 (48%) |
| 1 | 358 (52%) |
| ppi | |
| 0 | 137 (20%) |
| 1 | 545 (80%) |
| steroids | |
| 0 | 205 (30%) |
| 1 | 477 (70%) |
| smoking | |
| 0 | 334 (49%) |
| 1 | 348 (51%) |
| Bevacizumab | |
| 0 | 655 (96%) |
| 1 | 27 (4.0%) |
| Cisplatin | |
| 0 | 632 (93%) |
| 1 | 50 (7.3%) |
| Carboplatin | |
| 0 | 572 (84%) |
| 1 | 110 (16%) |
| Pemetrexed | |
| 0 | 626 (92%) |
| 1 | 56 (8.2%) |
| Gemcitabine | |
| 0 | 643 (94%) |
| 1 | 39 (5.7%) |
| Cetuximab | |
| 0 | 677 (99%) |
| 1 | 5 (0.7%) |
| Trastuzumab | |
| 0 | 669 (98%) |
| 1 | 13 (1.9%) |
| VEGF_TKI | |
| 0 | 642 (94%) |
| 1 | 40 (5.9%) |
| pre_CRE_180days | 0.87 (0.73, 1.04) |
| pre_HGB_180days | 13.20 (12.00, 14.10) |
| pre_ALB_180days | 4.20 (3.90, 4.40) |
| Unknown | 3 |
| eGFR_CRE_baseline | 91 (74, 101) |
| 1 Median (Q1, Q3); n (%) | |
8year
| Characteristic | N = 3981 |
|---|---|
| Age | 71 (61, 78) |
| Gender_Legal_Sex | |
| Female | 165 (41%) |
| Male | 233 (59%) |
| male | |
| 0 | 165 (41%) |
| 1 | 233 (59%) |
| Race | |
| Asian | 5 (1.3%) |
| Black | 7 (1.8%) |
| Other/Unknown | 10 (2.5%) |
| White | 376 (94%) |
| Ethnic_Group | |
| Hispanic | 358 (90%) |
| Non_hispanic | 40 (10%) |
| ckd_incidence_8year | |
| 0 | 338 (85%) |
| 1 | 60 (15%) |
| ckd_progression_8year | |
| 0 | 362 (91%) |
| 1 | 36 (9.0%) |
| eskd_composite_8year | |
| 0 | 394 (99%) |
| 1 | 4 (1.0%) |
| ckd_composite_8year | |
| 0 | 301 (76%) |
| 1 | 97 (24%) |
| ckd_stage_1year | |
| 1 | 172 (43%) |
| 2 | 181 (45%) |
| 3 | 45 (11%) |
| 4 | 0 (0%) |
| 5 | 0 (0%) |
| ckd_stage_2year | |
| 1 | 156 (39%) |
| 2 | 192 (48%) |
| 3 | 50 (13%) |
| 4 | 0 (0%) |
| 5 | 0 (0%) |
| ckd_stage_3year | |
| 1 | 147 (37%) |
| 2 | 198 (50%) |
| 3 | 53 (13%) |
| 4 | 0 (0%) |
| 5 | 0 (0%) |
| ckd_stage_4year | |
| 1 | 154 (39%) |
| 2 | 187 (47%) |
| 3 | 56 (14%) |
| 4 | 1 (0.3%) |
| 5 | 0 (0%) |
| ckd_stage_5year | |
| 1 | 155 (39%) |
| 2 | 182 (46%) |
| 3 | 59 (15%) |
| 4 | 2 (0.5%) |
| 5 | 0 (0%) |
| ckd_stage_6year | |
| 1 | 152 (38%) |
| 2 | 185 (46%) |
| 3 | 58 (15%) |
| 4 | 3 (0.8%) |
| 5 | 0 (0%) |
| ckd_stage_7year | |
| 1 | 151 (38%) |
| 2 | 187 (47%) |
| 3 | 55 (14%) |
| 4 | 5 (1.3%) |
| 5 | 0 (0%) |
| ckd_stage_8year | |
| 1 | 147 (37%) |
| 2 | 187 (47%) |
| 3 | 58 (15%) |
| 4 | 6 (1.5%) |
| 5 | 0 (0%) |
| ckd_stage_baseline | |
| 1 | 205 (52%) |
| 2 | 155 (39%) |
| 3 | 38 (9.5%) |
| 4 | 0 (0%) |
| 5 | 0 (0%) |
| dm | |
| 0 | 357 (90%) |
| 1 | 41 (10%) |
| htn | |
| 0 | 152 (38%) |
| 1 | 246 (62%) |
| cad | |
| 0 | 337 (85%) |
| 1 | 61 (15%) |
| ace_arb | |
| 0 | 209 (53%) |
| 1 | 189 (47%) |
| diu | |
| 0 | 195 (49%) |
| 1 | 203 (51%) |
| ppi | |
| 0 | 83 (21%) |
| 1 | 315 (79%) |
| steroids | |
| 0 | 141 (35%) |
| 1 | 257 (65%) |
| smoking | |
| 0 | 207 (52%) |
| 1 | 191 (48%) |
| Bevacizumab | |
| 0 | 383 (96%) |
| 1 | 15 (3.8%) |
| Cisplatin | |
| 0 | 374 (94%) |
| 1 | 24 (6.0%) |
| Carboplatin | |
| 0 | 346 (87%) |
| 1 | 52 (13%) |
| Pemetrexed | |
| 0 | 371 (93%) |
| 1 | 27 (6.8%) |
| Gemcitabine | |
| 0 | 382 (96%) |
| 1 | 16 (4.0%) |
| Cetuximab | |
| 0 | 395 (99%) |
| 1 | 3 (0.8%) |
| Trastuzumab | |
| 0 | 393 (99%) |
| 1 | 5 (1.3%) |
| VEGF_TKI | |
| 0 | 378 (95%) |
| 1 | 20 (5.0%) |
| pre_CRE_180days | 0.87 (0.75, 1.03) |
| pre_HGB_180days | 13.20 (12.00, 14.20) |
| pre_ALB_180days | 4.20 (4.00, 4.40) |
| Unknown | 2 |
| eGFR_CRE_baseline | 91 (75, 101) |
| 1 Median (Q1, Q3); n (%) | |
9year
| Characteristic | N = 2091 |
|---|---|
| Age | 71 (62, 78) |
| Gender_Legal_Sex | |
| Female | 90 (43%) |
| Male | 119 (57%) |
| male | |
| 0 | 90 (43%) |
| 1 | 119 (57%) |
| Race | |
| Asian | 2 (1.0%) |
| Black | 2 (1.0%) |
| Other/Unknown | 4 (1.9%) |
| White | 201 (96%) |
| Ethnic_Group | |
| Hispanic | 191 (91%) |
| Non_hispanic | 18 (8.6%) |
| ckd_incidence_9year | |
| 0 | 179 (86%) |
| 1 | 30 (14%) |
| ckd_progression_9year | |
| 0 | 190 (91%) |
| 1 | 19 (9.1%) |
| eskd_composite_9year | |
| 0 | 208 (100%) |
| 1 | 1 (0.5%) |
| ckd_composite_9year | |
| 0 | 160 (77%) |
| 1 | 49 (23%) |
| ckd_stage_1year | |
| 1 | 91 (44%) |
| 2 | 98 (47%) |
| 3 | 20 (9.6%) |
| 4 | 0 (0%) |
| 5 | 0 (0%) |
| ckd_stage_2year | |
| 1 | 86 (41%) |
| 2 | 103 (49%) |
| 3 | 20 (9.6%) |
| 4 | 0 (0%) |
| 5 | 0 (0%) |
| ckd_stage_3year | |
| 1 | 81 (39%) |
| 2 | 106 (51%) |
| 3 | 22 (11%) |
| 4 | 0 (0%) |
| 5 | 0 (0%) |
| ckd_stage_4year | |
| 1 | 90 (43%) |
| 2 | 94 (45%) |
| 3 | 25 (12%) |
| 4 | 0 (0%) |
| 5 | 0 (0%) |
| ckd_stage_5year | |
| 1 | 89 (43%) |
| 2 | 91 (44%) |
| 3 | 29 (14%) |
| 4 | 0 (0%) |
| 5 | 0 (0%) |
| ckd_stage_6year | |
| 1 | 83 (40%) |
| 2 | 95 (45%) |
| 3 | 31 (15%) |
| 4 | 0 (0%) |
| 5 | 0 (0%) |
| ckd_stage_7year | |
| 1 | 90 (43%) |
| 2 | 89 (43%) |
| 3 | 30 (14%) |
| 4 | 0 (0%) |
| 5 | 0 (0%) |
| ckd_stage_8year | |
| 1 | 90 (43%) |
| 2 | 87 (42%) |
| 3 | 31 (15%) |
| 4 | 1 (0.5%) |
| 5 | 0 (0%) |
| ckd_stage_9year | |
| 1 | 91 (44%) |
| 2 | 82 (39%) |
| 3 | 36 (17%) |
| 4 | 0 (0%) |
| 5 | 0 (0%) |
| ckd_stage_baseline | |
| 1 | 105 (50%) |
| 2 | 85 (41%) |
| 3 | 19 (9.1%) |
| 4 | 0 (0%) |
| 5 | 0 (0%) |
| dm | |
| 0 | 190 (91%) |
| 1 | 19 (9.1%) |
| htn | |
| 0 | 73 (35%) |
| 1 | 136 (65%) |
| cad | |
| 0 | 187 (89%) |
| 1 | 22 (11%) |
| ace_arb | |
| 0 | 119 (57%) |
| 1 | 90 (43%) |
| diu | |
| 0 | 102 (49%) |
| 1 | 107 (51%) |
| ppi | |
| 0 | 42 (20%) |
| 1 | 167 (80%) |
| steroids | |
| 0 | 89 (43%) |
| 1 | 120 (57%) |
| smoking | |
| 0 | 112 (54%) |
| 1 | 97 (46%) |
| Bevacizumab | |
| 0 | 200 (96%) |
| 1 | 9 (4.3%) |
| Cisplatin | |
| 0 | 200 (96%) |
| 1 | 9 (4.3%) |
| Carboplatin | |
| 0 | 185 (89%) |
| 1 | 24 (11%) |
| Pemetrexed | |
| 0 | 197 (94%) |
| 1 | 12 (5.7%) |
| Gemcitabine | |
| 0 | 202 (97%) |
| 1 | 7 (3.3%) |
| Cetuximab | |
| 0 | 207 (99%) |
| 1 | 2 (1.0%) |
| Trastuzumab | |
| 0 | 206 (99%) |
| 1 | 3 (1.4%) |
| VEGF_TKI | |
| 0 | 200 (96%) |
| 1 | 9 (4.3%) |
| pre_CRE_180days | 0.88 (0.76, 1.05) |
| pre_HGB_180days | 13.40 (12.00, 14.30) |
| pre_ALB_180days | 4.30 (4.10, 4.50) |
| eGFR_CRE_baseline | 90 (74, 102) |
| 1 Median (Q1, Q3); n (%) | |
10year
| Characteristic | N = 741 |
|---|---|
| Age | 72 (61, 79) |
| Gender_Legal_Sex | |
| Female | 35 (47%) |
| Male | 39 (53%) |
| male | |
| 0 | 35 (47%) |
| 1 | 39 (53%) |
| Race | |
| Asian | 0 (0%) |
| Black | 0 (0%) |
| Other/Unknown | 1 (1.4%) |
| White | 73 (99%) |
| Ethnic_Group | |
| Hispanic | 69 (93%) |
| Non_hispanic | 5 (6.8%) |
| ckd_incidence_10year | |
| 0 | 64 (86%) |
| 1 | 10 (14%) |
| ckd_progression_10year | |
| 0 | 65 (88%) |
| 1 | 9 (12%) |
| eskd_composite_10year | |
| 0 | 73 (99%) |
| 1 | 1 (1.4%) |
| ckd_composite_10year | |
| 0 | 55 (74%) |
| 1 | 19 (26%) |
| ckd_stage_1year | |
| 1 | 33 (45%) |
| 2 | 30 (41%) |
| 3 | 11 (15%) |
| 4 | 0 (0%) |
| 5 | 0 (0%) |
| ckd_stage_2year | |
| 1 | 32 (43%) |
| 2 | 32 (43%) |
| 3 | 10 (14%) |
| 4 | 0 (0%) |
| 5 | 0 (0%) |
| ckd_stage_3year | |
| 1 | 31 (42%) |
| 2 | 32 (43%) |
| 3 | 11 (15%) |
| 4 | 0 (0%) |
| 5 | 0 (0%) |
| ckd_stage_4year | |
| 1 | 31 (42%) |
| 2 | 30 (41%) |
| 3 | 13 (18%) |
| 4 | 0 (0%) |
| 5 | 0 (0%) |
| ckd_stage_5year | |
| 1 | 31 (42%) |
| 2 | 31 (42%) |
| 3 | 12 (16%) |
| 4 | 0 (0%) |
| 5 | 0 (0%) |
| ckd_stage_6year | |
| 1 | 28 (38%) |
| 2 | 34 (46%) |
| 3 | 12 (16%) |
| 4 | 0 (0%) |
| 5 | 0 (0%) |
| ckd_stage_7year | |
| 1 | 28 (38%) |
| 2 | 33 (45%) |
| 3 | 13 (18%) |
| 4 | 0 (0%) |
| 5 | 0 (0%) |
| ckd_stage_8year | |
| 1 | 27 (36%) |
| 2 | 33 (45%) |
| 3 | 13 (18%) |
| 4 | 1 (1.4%) |
| 5 | 0 (0%) |
| ckd_stage_9year | |
| 1 | 30 (41%) |
| 2 | 30 (41%) |
| 3 | 14 (19%) |
| 4 | 0 (0%) |
| 5 | 0 (0%) |
| ckd_stage_10year | |
| 1 | 28 (38%) |
| 2 | 33 (45%) |
| 3 | 10 (14%) |
| 4 | 3 (4.1%) |
| 5 | 0 (0%) |
| ckd_stage_baseline | |
| 1 | 39 (53%) |
| 2 | 25 (34%) |
| 3 | 10 (14%) |
| 4 | 0 (0%) |
| 5 | 0 (0%) |
| dm | |
| 0 | 67 (91%) |
| 1 | 7 (9.5%) |
| htn | |
| 0 | 26 (35%) |
| 1 | 48 (65%) |
| cad | |
| 0 | 66 (89%) |
| 1 | 8 (11%) |
| ace_arb | |
| 0 | 38 (51%) |
| 1 | 36 (49%) |
| diu | |
| 0 | 35 (47%) |
| 1 | 39 (53%) |
| ppi | |
| 0 | 16 (22%) |
| 1 | 58 (78%) |
| steroids | |
| 0 | 41 (55%) |
| 1 | 33 (45%) |
| smoking | |
| 0 | 34 (46%) |
| 1 | 40 (54%) |
| Bevacizumab | |
| 0 | 71 (96%) |
| 1 | 3 (4.1%) |
| Cisplatin | |
| 0 | 72 (97%) |
| 1 | 2 (2.7%) |
| Carboplatin | |
| 0 | 69 (93%) |
| 1 | 5 (6.8%) |
| Pemetrexed | |
| 0 | 70 (95%) |
| 1 | 4 (5.4%) |
| Gemcitabine | |
| 0 | 73 (99%) |
| 1 | 1 (1.4%) |
| Cetuximab | |
| 0 | 74 (100%) |
| Trastuzumab | |
| 0 | 72 (97%) |
| 1 | 2 (2.7%) |
| VEGF_TKI | |
| 0 | 72 (97%) |
| 1 | 2 (2.7%) |
| pre_CRE_180days | 0.86 (0.78, 1.03) |
| pre_HGB_180days | 13.65 (12.50, 14.50) |
| pre_ALB_180days | 4.40 (4.20, 4.70) |
| eGFR_CRE_baseline | 91 (74, 101) |
| 1 Median (Q1, Q3); n (%) | |
landmark 1year
landmark 2year
landmark 3year
landmark 4year
landmark 5year
# ckd_stage vs ckd_composite_5year
| 0 (N=1362) |
1 (N=357) |
Overall (N=1719) |
|
|---|---|---|---|
| ckd_stage_baseline_3 | |||
| stage 1 | 760 (55.8%) | 59 (16.5%) | 819 (47.6%) |
| stage 2 | 567 (41.6%) | 139 (38.9%) | 706 (41.1%) |
| stage 3 or more | 35 (2.6%) | 159 (44.5%) | 194 (11.3%) |
| ckd_stage_5year_3 | |||
| stage 1 | 618 (45.4%) | 10 (2.8%) | 628 (36.5%) |
| stage 2 | 675 (49.6%) | 112 (31.4%) | 787 (45.8%) |
| stage 3 or more | 69 (5.1%) | 235 (65.8%) | 304 (17.7%) |
ckd_stage vs ckd_composite_5year
| 0 (N=1362) |
1 (N=357) |
Overall (N=1719) |
|
|---|---|---|---|
| ckd_stage_baseline_3 | |||
| stage 1 | 760 (55.8%) | 59 (16.5%) | 819 (47.6%) |
| stage 2 | 567 (41.6%) | 139 (38.9%) | 706 (41.1%) |
| stage 3 or more | 35 (2.6%) | 159 (44.5%) | 194 (11.3%) |
| ckd_stage_5year_3 | |||
| stage 1 | 618 (45.4%) | 10 (2.8%) | 628 (36.5%) |
| stage 2 | 675 (49.6%) | 112 (31.4%) | 787 (45.8%) |
| stage 3 or more | 69 (5.1%) | 235 (65.8%) | 304 (17.7%) |
ckd_stage vs ckd_composite_5year
| 0 (N=1362) |
1 (N=357) |
Overall (N=1719) |
|
|---|---|---|---|
| ckd_stage_baseline_3 | |||
| stage 1 | 760 (55.8%) | 59 (16.5%) | 819 (47.6%) |
| stage 2 | 567 (41.6%) | 139 (38.9%) | 706 (41.1%) |
| stage 3 or more | 35 (2.6%) | 159 (44.5%) | 194 (11.3%) |
| ckd_stage_5year_3 | |||
| stage 1 | 618 (45.4%) | 10 (2.8%) | 628 (36.5%) |
| stage 2 | 675 (49.6%) | 112 (31.4%) | 787 (45.8%) |
| stage 3 or more | 69 (5.1%) | 235 (65.8%) | 304 (17.7%) |
ckd_stage vs ckd_composite_5year
| 0 (N=1362) |
1 (N=357) |
Overall (N=1719) |
|
|---|---|---|---|
| ckd_stage_baseline_3 | |||
| stage 1 | 760 (55.8%) | 59 (16.5%) | 819 (47.6%) |
| stage 2 | 567 (41.6%) | 139 (38.9%) | 706 (41.1%) |
| stage 3 or more | 35 (2.6%) | 159 (44.5%) | 194 (11.3%) |
| ckd_stage_5year_3 | |||
| stage 1 | 618 (45.4%) | 10 (2.8%) | 628 (36.5%) |
| stage 2 | 675 (49.6%) | 112 (31.4%) | 787 (45.8%) |
| stage 3 or more | 69 (5.1%) | 235 (65.8%) | 304 (17.7%) |
ckd_stage vs ckd_composite_5year
| 0 (N=1362) |
1 (N=357) |
Overall (N=1719) |
|
|---|---|---|---|
| ckd_stage_baseline_3 | |||
| stage 1 | 760 (55.8%) | 59 (16.5%) | 819 (47.6%) |
| stage 2 | 567 (41.6%) | 139 (38.9%) | 706 (41.1%) |
| stage 3 or more | 35 (2.6%) | 159 (44.5%) | 194 (11.3%) |
| ckd_stage_5year_3 | |||
| stage 1 | 618 (45.4%) | 10 (2.8%) | 628 (36.5%) |
| stage 2 | 675 (49.6%) | 112 (31.4%) | 787 (45.8%) |
| stage 3 or more | 69 (5.1%) | 235 (65.8%) | 304 (17.7%) |
logistic regression outcome: ckd_composite_5year
| Characteristic | N | OR1 | 95% CI1 | p-value |
|---|---|---|---|---|
| year_10 | 1,719 | 2.02 | 1.80, 2.28 | <0.001 |
| Gender_Legal_Sex | 1,719 | |||
| Female | — | — | ||
| Male | 1.00 | 0.79, 1.26 | 0.987 | |
| male | 1,719 | |||
| 0 | — | — | ||
| 1 | 1.00 | 0.79, 1.26 | 0.987 | |
| Race | 1,719 | |||
| Asian | — | — | ||
| Black | 3.91 | 1.25, 13.3 | 0.022 | |
| Other/Unknown | 1.07 | 0.36, 3.40 | 0.909 | |
| White | 1.39 | 0.62, 3.72 | 0.462 | |
| dm | 1,719 | |||
| 0 | — | — | ||
| 1 | 2.16 | 1.54, 2.99 | <0.001 | |
| htn | 1,719 | |||
| 0 | — | — | ||
| 1 | 2.28 | 1.77, 2.97 | <0.001 | |
| cad | 1,719 | |||
| 0 | — | — | ||
| 1 | 1.98 | 1.50, 2.60 | <0.001 | |
| ace_arb | 1,719 | |||
| 0 | — | — | ||
| 1 | 3.03 | 2.37, 3.89 | <0.001 | |
| diu | 1,719 | |||
| 0 | — | — | ||
| 1 | 3.21 | 2.49, 4.18 | <0.001 | |
| ppi | 1,719 | |||
| 0 | — | — | ||
| 1 | 1.57 | 1.18, 2.12 | 0.003 | |
| steroids | 1,719 | |||
| 0 | — | — | ||
| 1 | 0.79 | 0.62, 1.02 | 0.071 | |
| smoking | 1,719 | |||
| 0 | — | — | ||
| 1 | 1.40 | 1.10, 1.77 | 0.006 | |
| statins | 1,719 | 1.92 | 1.51, 2.46 | <0.001 |
| Bevacizumab | 1,719 | |||
| 0 | — | — | ||
| 1 | 1.19 | 0.68, 2.01 | 0.522 | |
| Cisplatin | 1,719 | |||
| 0 | — | — | ||
| 1 | 1.15 | 0.79, 1.64 | 0.467 | |
| Carboplatin | 1,719 | |||
| 0 | — | — | ||
| 1 | 1.03 | 0.77, 1.37 | 0.833 | |
| Pemetrexed | 1,719 | |||
| 0 | — | — | ||
| 1 | 1.43 | 0.99, 2.03 | 0.053 | |
| Gemcitabine | 1,719 | |||
| 0 | — | — | ||
| 1 | 1.80 | 1.23, 2.60 | 0.002 | |
| Cetuximab | 1,719 | |||
| 0 | — | — | ||
| 1 | 0.63 | 0.15, 1.88 | 0.465 | |
| Trastuzumab | 1,719 | |||
| 0 | — | — | ||
| 1 | 0.63 | 0.21, 1.50 | 0.344 | |
| VEGF_TKI | 1,719 | |||
| 0 | — | — | ||
| 1 | 3.49 | 2.36, 5.16 | <0.001 | |
| eGFR_CRE_5year_decrease_10 | 1,719 | 3.31 | 2.93, 3.78 | <0.001 |
| ICI_Class | 1,719 | |||
| PD1 | — | — | ||
| Combination | 0.79 | 0.53, 1.15 | 0.241 | |
| CTLA4 | 0.94 | 0.58, 1.48 | 0.810 | |
| PDL1 | 1.26 | 0.89, 1.76 | 0.190 | |
| cancer_type | 1,719 | |||
| breast | — | — | ||
| Breast | 269,587 | 0.00, |
0.984 | |
| Cutaneous / Melanoma | 349,193 | 0.00, |
0.984 | |
| gi | 1.00 | 0.00, 686 | >0.999 | |
| GI | 784,511 | 0.00, |
0.983 | |
| GU | 1,634,501 | 0.00, |
0.982 | |
| gyn | 1.00 | 0.02, 53.2 | >0.999 | |
| GYN | 585,880 | 0.00, |
0.983 | |
| Head and Neck | 427,915 | 0.00, |
0.983 | |
| Heme | 353,030 | 0.00, |
0.984 | |
| Neuro | 226,948 | 0.00, |
0.984 | |
| Sarcoma | 423,636 | 0.00, |
0.983 | |
| thoracic | 1,270,908 | 0.00, |
0.982 | |
| Thoracic | 620,712 | 0.00, |
0.983 | |
| pre_CRE_180days | 1,719 | 57.4 | 34.3, 98.4 | <0.001 |
| 1 OR = Odds Ratio, CI = Confidence Interval | ||||
cox model outcome: death
| Characteristic | N | HR1 | 95% CI1 | p-value |
|---|---|---|---|---|
| year_10 | 1,719 | 0.99 | 0.95, 1.03 | 0.576 |
| Gender_Legal_Sex | 1,719 | |||
| Female | — | — | ||
| Male | 0.96 | 0.88, 1.06 | 0.451 | |
| male | 1,719 | |||
| 0 | — | — | ||
| 1 | 0.96 | 0.88, 1.06 | 0.451 | |
| Race | 1,719 | |||
| Asian | — | — | ||
| Black | 0.65 | 0.39, 1.07 | 0.089 | |
| Other/Unknown | 0.79 | 0.53, 1.19 | 0.266 | |
| White | 0.70 | 0.51, 0.97 | 0.033 | |
| dm | 1,719 | |||
| 0 | — | — | ||
| 1 | 1.01 | 0.86, 1.17 | 0.935 | |
| htn | 1,719 | |||
| 0 | — | — | ||
| 1 | 0.93 | 0.84, 1.02 | 0.120 | |
| cad | 1,719 | |||
| 0 | — | — | ||
| 1 | 1.20 | 1.06, 1.36 | 0.003 | |
| ace_arb | 1,719 | |||
| 0 | — | — | ||
| 1 | 1.02 | 0.93, 1.12 | 0.675 | |
| diu | 1,719 | |||
| 0 | — | — | ||
| 1 | 1.03 | 0.94, 1.14 | 0.507 | |
| ppi | 1,719 | |||
| 0 | — | — | ||
| 1 | 0.86 | 0.77, 0.96 | 0.008 | |
| steroids | 1,719 | |||
| 0 | — | — | ||
| 1 | 1.21 | 1.09, 1.35 | <0.001 | |
| smoking | 1,719 | |||
| 0 | — | — | ||
| 1 | 1.05 | 0.95, 1.15 | 0.331 | |
| ckd_stage_baseline_3 | 1,719 | |||
| stage 1 | — | — | ||
| stage 2 | 1.09 | 0.99, 1.21 | 0.092 | |
| stage 3 or more | 1.12 | 0.95, 1.31 | 0.167 | |
| ckd_stage_5year_3 | 1,719 | |||
| stage 1 | — | — | ||
| stage 2 | 1.07 | 0.96, 1.19 | 0.201 | |
| stage 3 or more | 1.19 | 1.04, 1.37 | 0.012 | |
| Bevacizumab | 1,719 | |||
| 0 | — | — | ||
| 1 | 1.08 | 0.86, 1.35 | 0.531 | |
| Cisplatin | 1,719 | |||
| 0 | — | — | ||
| 1 | 1.35 | 1.16, 1.58 | <0.001 | |
| Carboplatin | 1,719 | |||
| 0 | — | — | ||
| 1 | 1.35 | 1.20, 1.52 | <0.001 | |
| Pemetrexed | 1,719 | |||
| 0 | — | — | ||
| 1 | 1.24 | 1.06, 1.45 | 0.008 | |
| Gemcitabine | 1,719 | |||
| 0 | — | — | ||
| 1 | 1.46 | 1.23, 1.73 | <0.001 | |
| Cetuximab | 1,719 | |||
| 0 | — | — | ||
| 1 | 1.47 | 0.95, 2.26 | 0.080 | |
| Trastuzumab | 1,719 | |||
| 0 | — | — | ||
| 1 | 1.07 | 0.77, 1.50 | 0.692 | |
| VEGF_TKI | 1,719 | |||
| 0 | — | — | ||
| 1 | 1.22 | 1.01, 1.47 | 0.043 | |
| ICI_Class | 1,719 | |||
| PD1 | — | — | ||
| Combination | 0.86 | 0.75, 1.00 | 0.052 | |
| CTLA4 | 0.36 | 0.30, 0.44 | <0.001 | |
| PDL1 | 1.06 | 0.91, 1.22 | 0.460 | |
| cancer_type | 1,719 | |||
| breast | — | — | ||
| Breast | 0.13 | 0.03, 0.53 | 0.005 | |
| Cutaneous / Melanoma | 0.08 | 0.02, 0.34 | <0.001 | |
| gi | 1.78 | 0.16, 19.6 | 0.639 | |
| GI | 0.21 | 0.05, 0.87 | 0.031 | |
| GU | 0.15 | 0.04, 0.59 | 0.007 | |
| gyn | 0.52 | 0.07, 3.69 | 0.512 | |
| GYN | 0.17 | 0.04, 0.71 | 0.015 | |
| Head and Neck | 0.18 | 0.05, 0.75 | 0.018 | |
| Heme | 0.09 | 0.02, 0.38 | <0.001 | |
| Neuro | 0.19 | 0.05, 0.81 | 0.025 | |
| Sarcoma | 0.33 | 0.07, 1.48 | 0.148 | |
| thoracic | 1.05 | 0.24, 4.56 | 0.949 | |
| Thoracic | 0.14 | 0.04, 0.58 | 0.007 | |
| eGFR_CRE_baseline_decrease_10 | 1,719 | 1.02 | 1.0, 1.04 | 0.126 |
| pre_CRE_180days | 1,719 | 1.05 | 0.87, 1.25 | 0.624 |
| ckd_composite_5year | 1,719 | |||
| 0 | — | — | ||
| 1 | 1.13 | 1.00, 1.27 | 0.045 | |
| 1 HR = Hazard Ratio, CI = Confidence Interval | ||||